- Home
- IEAG vs OVID Comparison
IEAG vs OVID Comparison
Compare IEAG & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$2.46
Company Overview
Basic Information| Metric | IEAG | OVID |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 436.9M | 522.6M |
| IPO Year | 2026 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IEAG | OVID |
|---|---|---|
| Price | $10.03 | $2.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 66.3K | ★ 1.7M |
| Earning Date | N/A | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $9.97 | $0.27 |
| 52 Week High | $10.08 | $3.11 |
Technical Indicators
Market Signals| Indicator | IEAG | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 50.93 | 42.00 |
| Support Level | $10.00 | $1.95 |
| Resistance Level | $10.06 | $2.72 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 38.67 | 20.45 |
Price Performance
Historical Comparison IEAG
OVID
About IEAG Infinite Eagle Acquisition Corp. Class A Ordinary Shares
Infinite Eagle Acquisition Corp is a blank check company.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.